Clinical trials were performed with two checkpoint inhibitors in HCC: the anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) agent tremelimumab [11] as well as the anti-programmed death 1 (PD-1) agent nivolumab [12]. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.